Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Sarcoma 7Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Salivary Gland Neoplasms 3Head and Neck Neoplasms 3Gastrointestinal Stromal Tumors 3Central Nervous System Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Thyroid Diseases 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neuroblastoma 2Neoplasms by Site 2Melanoma 2Medulloblastoma 2Lung Neoplasms 2Lung Diseases 2Glioma 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2

Interventions

venetoclax 1pirtobrutinib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Waldenstrom Macroglobulinemia × Sarcoma × Clear all
NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡